The excerpt is a standard boilerplate header for Item 5.02 and contains no specific details about any personnel changes.

Unregistered Sales of Equity Securities. To the extent required by this Item, the information included in

Entry into a Material Definitive Agreement. Merger Agreement On August 16, 2026, Fulcrum Therapeutics, Inc., a Delaware corporation (“Fulcrum”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) by and among Fulcrum, Fusion Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of Fulcrum, (“Merger Sub I”), Fusion Merger Sub II, LLC, a Delaware limited liability company and a wholly owned subsidiary of Fulcrum, (“Merger Sub II”), and Slate Medicines, Inc.,…

Changes in Control of Registrant. To the extent required by this Item, the information included in

Regulation FD Disclosure. On August 17, 2026, Fulcrum and Slate issued a joint press release announcing the execution of the Merger Agreement and the Purchase Agreement. The press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference, except that the information contained on the websites referenced in the press release is not incorporated herein by reference. Furnished as Exhibit 99.2 hereto and incorporated herein by reference is the inv…

Principal Accounting Officer — Greg Tourangeau: The Principal Accounting Officer departed via mutual agreement, but the role was immediately filled by the existing CFO, ensuring continuity and minimizing disruption.

The company approved retention payments and change in control benefits for senior executives as part of a restructuring plan.

Costs Associated with Exit or Disposal Activities. On May 31, 2026, the board of directors of Fulcrum Therapeutics, Inc., or Fulcrum, approved a restructuring plan to significantly reduce Fulcrum’s operating expenses and preserve capital following the discontinuation of development of pociredir for the treatment of sickle cell disease, or SCD. The restructuring plan will reduce Fulcrum’s workforce by approximately 85%, from 57 full-time employees to 9 full-time employees, and is expected to b…

Other Events. As previously disclosed, Fulcrum has initiated a comprehensive review of strategic alternatives intended to maximize stockholder value. In connection with this process, Fulcrum has engaged Leerink Partners LLC as its financial advisor to assist the Board of Directors in reviewing potential strategic alternatives, including, but not limited to, a merger, acquisition, business combination, sale or licensing of assets, or other strategic transaction involving the company or its ass…

Results of Operations and Financial Condition. On April 27, 2026, Fulcrum announced its financial results for the quarter ended March 31, 2026. The full text of the press release issued in connection with the announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of…

Chief Financial Officer — Alan Musso: The CFO is retiring and a successor has not yet been named.

Termination of a Material Definitive Agreement. On April 23, 2026, Fulcrum Therapeutics, Inc., or Fulcrum, provided written notice to CAMP4 Therapeutics Corp., or CAMP4, of termination of the License Agreement dated July 5, 2023, between Fulcrum and CAMP4, or the CAMP4 License, which termination will be effective in accordance with the terms of such agreement. Under the CAMP4 License, Fulcrum received a worldwide exclusive license (including the right to sublicense) from CAMP4 to rights under…

Results of Operations and Financial Condition. On February 24, 2026, Fulcrum Therapeutics, Inc., or Fulcrum, announced its financial results for the quarter and year ended December 31, 2025. The full text of the press release issued in connection with the announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes o…

Results of Operations and Financial Condition. Fulcrum Therapeutics, Inc., or Fulcrum, expects to report that it had cash, cash equivalents and marketable securities of approximately $352.3 million as of December 31, 2025. The estimated cash figure is preliminary and unaudited, represents a management estimate as of the date of this Current Report on Form 8-K and is subject to completion of Fulcrum's financial closing procedures. Fulcrum's independent registered public accounting firm has not…

Entry into a Material Definitive Agreement. On December 10, 2025, Fulcrum Therapeutics, Inc., or Fulcrum, entered into an underwriting agreement, or the Underwriting Agreement, with J.P. Morgan Securities LLC, Leerink Partners LLC, and Cantor Fitzgerald & Co., as the representatives of the several underwriters, or the Underwriters, relating to an underwritten public offering of (a) 11,851,853 shares, or the Firm Shares, of its common stock, par value $0.001 per share, or the Common Stock, at…

Other Events. On December 7, 2025, Fulcrum published a presentation announcing initial results of the 20 mg dose cohort of the Phase 1b PIONEER trial of pociredir in SCD in connection with a presentation at the 67th American Society of Hematology Annual Meeting. Results are as follows: • Mean absolute fetal hemoglobin, or HbF, increased by 9.9% at 6 weeks of treatment with pociredir (vs. 5.6% at Week 6 and 8.6% at Week 12 in the 12 mg cohort), increasing from a baseline of 7.1% to 16.9%. As o…

Results of Operations and Financial Condition. On October 29, 2025, Fulcrum Therapeutics, Inc., or Fulcrum, announced its financial results for the quarter ended September 30, 2025. The full text of the press release issued in connection with the announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section…

Results of Operations and Financial Condition. On July 29, 2025, Fulcrum Therapeutics, Inc., or Fulcrum, announced its financial results for the quarter ended June 30, 2025. The full text of the press release issued in connection with the announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of t…

Results of Operations and Financial Condition. On May 1, 2025, Fulcrum announced its financial results for the quarter ended March 31, 2025. The full text of the press release issued in connection with the announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 193…

Results of Operations and Financial Condition. On February 25, 2025, Fulcrum announced its financial results for the quarter ended December 31, 2024. The full text of the press release issued in connection with the announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange A…

of, and in Exhibit 99.1 attached to, this current report on Form 8-K is unaudited and preliminary and does not present all information necessary for an understanding of Fulcrum’s financial condition as of December 31, 2024. The audit of Fulcrum’s consolidated financial statements for the year ended December 31, 2024 is ongoing and could result in changes to the information set forth above. The information in this Item 2.02, and in Exhibit 99.1 attached hereto, shall not be deemed “filed” for…

Results of Operations and Financial Condition. On November 13, 2024, Fulcrum announced its financial results for the quarter ended September 30, 2024. The full text of the press release issued in connection with the announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange…

Director — James J. Collins: Dr. James J. Collins resigned as a director but will continue to advise the Board as a consultant.

Costs Associated with Exit or Disposal Activities. On September 24, 2024, Fulcrum announced the approval by its board of directors of a plan to reprioritize research and development activities to focus on advancing pociredir for the treatment of sickle cell disease, novel therapeutic agents for the treatment of Diamond-Blackfan anemia, and its early discovery programs. The plan will reduce the Company’s workforce from 80 to 51 full-time employees, including a reduction of positions across bot…

Unregistered Sales of Equity Securities. On August 21, 2024, we entered into separate exchange agreements with RA Capital Healthcare Fund, L.P., or RA Capital, and another existing institutional stockholder, pursuant to which (i) RA Capital exchanged 8,500,000 shares of our common stock, par value $0.001 per share, or common stock, for a pre-funded warrant to acquire 8,500,000 shares of our common stock and (ii) the other existing institutional stockholder exchanged an aggregate of 850,000 sh…